Press Release: Psycheceutical, Inc. Announces New Patents that Enable Psychedelic Compounds to be Administered as Pharmaceutical Medicines

CANNANNEW REPORT

Biotech startup to bring safety and efficacy to the emerging psychedelic industry, brings on University of Michigan Researcher as Chief Science Officer MIAMI, Aug. 19, 2021 /PRNewswire/ — Psycheceutical, Inc., a biotechnology company dedicated to the development and commercialization of psychedelic medicines, today announced its exclusive license within the entire psychedelic industry of two major patents that will significantly advance the medical application of psychedelic compounds. Psycheceutical’s patented delivery systems allow psychedelics, such as psilocybin, ibogaine, and ketamine, to be administered without unwanted side effects and toxicity by bypassing the stomach and the liver. Psycheceutical’s Janus particle solution uses layered nanoparticles to target specific cells and deliver multiple medicines at different times and rates. The patented delivery system was established following groundbreaking research conducted at the University of Michigan by Professor Dr. Anish Tuteja, who has now joined Psycheceutical as the Chief Science Officer. “The Janus particle technology has immense potential to transform the delivery of psychedelic therapies amid today’s mental health crisis. Nearly all forms of research being done on psychedelics are via the digestive tract, which slows uptake, requires higher dosage, and may lead to harmful side effects in the body. By leveraging nanoparticle encapsulation, Psycheceutical will overcome these limitations. Psycheceutical aims to provide similar nanoparticle-based solutions to any and all companies doing psychedelic drug development research,” said Dr. Tuteja. Psycheceutical’s second patented technology, the NeuroDirect™ delivery system, administers neuroactive compounds directly to nerve connections to the brain, bypassing the blood-brain-barrier. This delivery system allows for smaller doses, improved efficacy of the active compound, and immediate response in minutes. It also eliminates the potentially toxic and hallucinogenic effects of psychedelic compounds, facilitating wider medical adoption and use. Dr. Aung Din, who developed the NeuroDirect™ technology, said, “Having practiced neurology and neuropsychiatry for 30 years and been involved in clinical research to bring numerous drugs…

Excerpt only …
READ MORE BELOW
Source : Press Release: Psycheceutical, Inc. Announces New Patents that Enable Psychedelic Compounds to be Administered as Pharmaceutical Medicines

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.